From GenomeWeb:
In a study appearing online today in Cancer Immunology Research, investigators at Johns Hopkins University School of Medicine described differences in metabolic gene expression that coincided with response to Bristol-Myers Squibb’s anti-PD-1 drug Opdivo (nivolumab) in individuals with PD-L1-positive renal cell carcinoma (RCC) kidney cancers. The team did array-based gene expression profiling on tumor samples from 11 individuals with metastatic RCC, focusing on tumor sites that express the PD-L1 protein — one of several proposed markers for response to anti-PD-1 treatments.
Read the full story.
